Bertilimumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Template:Infobox drug/mab source |
Target | CCL11 (eotaxin-1) |
Identifiers | |
CAS Number | 375348-49-5 |
ATC code | none |
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1.
It was discovered by Cambridge Antibody Technology using their phage display technology[1]. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders[2].
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3]. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'[4].
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis[5].
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/15573873
- ↑ http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/
- ↑ http://www.icotherapeutics.com/site/corporate_overview/overview/
- ↑ http://www.icotherapeutics.com/site/pipeline/ico008/
- ↑ http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs